1365-2141/asset/olbannerleft.gif?v=1&s=2237887a0dba115836e329b1c5824f93749b814b)
1365-2141/asset/olbannerright.gif?v=1&s=01b5795d608a5571b530fcd8eb300f01b48de3b2)
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
Article first published online: 24 DEC 2001
DOI: 10.1046/j.1365-2141.2000.02093.x
1365-2141/asset/cover.gif?v=1&s=340532f3ee73ba9171e38abd4d7f6a926d117661 "British Journal of Haematology")
Additional Information
How to Cite
Moreau, P., Harousseau, J.-L., Wijdenes, J., Morineau, N., Milpied, N. and Bataille, R. (2000), A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. British Journal of Haematology, 109: 661–664. doi: 10.1046/j.1365-2141.2000.02093.x
Publication History
- Issue published online: 24 DEC 2001
- Article first published online: 24 DEC 2001
- Received 11 February 2000; accepted for publication 16 February 2000
- Abstract
- Article
- References
- Cited By
Keywords:
- multiple myeloma;
- high-dose melphalan;
- anti-IL-6 monoclonal antibody;
- autologous stem cell transplantation;
- conditioning regimen
To improve the complete response (CR) rate in advanced multiple myeloma (MM) without increasing the toxicity of high-dose therapy, we have used a new conditioning regimen. A combination of BE-8 [an anti-interleukin 6 (IL-6) murine monoclonal antibody] and dexamethasone followed by high-dose melphalan (220 mg/m2) and autologous stem cell transplantation was used to treat a series of 16 patients with advanced multiple myeloma. A strong inhibition of IL-6 activity evaluated by quantification of C-reactive protein was observed in all patients and was correlated with the high CR rate achieved with this combination therapy.